Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 12/20 | 0.39 |
| ▸ | BRD4 | O60885 | 2/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | PTGES | O14684 | 3/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | SLC8A1 | P32418 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5106333 | 1.00 | DHODH (0.39) | DHODHBRD4RIPK1PTGESPARP1 | |
| Oxalic Acid SCHEMBL5657472 | 0.98 | DHODH (0.38) | DHODHBRD4RIPK1PTGESPARP1 | |
| SCHEMBL1943187 | 0.90 | DHODH (0.33) | DHODHPTGESPARP1SLC8A1 | |
| SCHEMBL4961983 | 0.89 | DHODH (0.35) | DHODHPTGESPARP1SLC8A1 | |
| SCHEMBL5506770 | 0.88 | DHODH (0.34) | DHODH | |
| SCHEMBL4664616 | 0.80 | RIPK1 (0.36) | DHODHBRD4RIPK1SLC8A1 | |
| SCHEMBL4662902 | 0.80 | RIPK1 (0.36) | DHODHBRD4RIPK1SLC8A1 | |
| SCHEMBL4663156 | 0.80 | RIPK1 (0.36) | DHODHBRD4RIPK1SLC8A1 | |
| SCHEMBL4664631 | 0.76 | PARP1 (0.36) | BRD4RIPK1PARP1SLC8A1 | |
| SCHEMBL4664769 | 0.76 | RIPK1 (0.36) | BRD4RIPK1SLC8A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7307084-B2 | Cyclic benzimidazoles | ALTANA PHARMA AG (DE) | 2007-12-11 | — | — | US | claimed |
| US-20080113963-A1 | Cyclic benzimidazoles | ALTANA PHARMA AG (DE) | 2008-05-15 | — | — | US | disclosed |
| US-7307084-B2 | Cyclic benzimidazoles | ALTANA PHARMA AG (DE) | 2007-12-11 | — | — | US | disclosed |
| US-20060194968-A1 | Cyclic benizimidazoles | ALTANA PHARMA AG (DE) | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194968-A1 | Cyclic benizimidazoles | VIP, SI, GIPR | DHODH 2936/4885BRD4 85/4885RIPK1 4446/4885 |
| US-20080113963-A1 | Cyclic benzimidazoles | VIP, GIPR, SI | DHODH 3933/4885BRD4 1068/4885RIPK1 4185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.